Eli Lilly sued Southend Pharmacy on October 27, 2025, accusing the Houston-based compounding pharmacy of illegally mass-producing “replicas” of its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound. The Southend Pharmacy lawsuit is one piece of a nationwide campaign Lilly has waged against companies selling compounded tirzepatide, the active ingredient in both drugs, with claims now filed in more than 34 states.1Texas Lawyer. Eli Lilly Sues 2 Texas Companies for Allegedly Selling Replicas of Weight-Loss Drugs
Who Southend Pharmacy Is
Southend is a 503A compounding pharmacy, meaning it compounds patient-specific medications on the strength of individual prescriptions under state board oversight rather than FDA pre-approval. It operates from a 55,200-square-foot facility in Houston and holds licenses in 36 states.2Southend Pharmacy. Southend Pharmacy Its business is provider-facing rather than direct-to-consumer; confirmed telehealth partners include Mochi Health and Brello Health.3Bariatric Reports. Southend Pharmacy
The catalog at the center of Lilly’s complaint includes an injectable formulation of tirzepatide combined with pyridoxine HCl (vitamin B6), alongside a semaglutide-plus-B6 product and other metabolic compounds.4Southend Pharmacy. Southend Pharmacy Products Southend states it maintains LegitScript certification and complies with USP <797> sterile compounding guidelines.2Southend Pharmacy. Southend Pharmacy As of March 2026, no FDA warning letters or state enforcement actions against the company had been publicly reported.3Bariatric Reports. Southend Pharmacy
What Lilly Is Alleging
The Southend complaint was one of two suits Lilly filed against Texas compounding pharmacies on October 27, 2025, both accusing the defendants of illegally mass-producing knockoff Mounjaro and Zepbound.1Texas Lawyer. Eli Lilly Sues 2 Texas Companies for Allegedly Selling Replicas of Weight-Loss Drugs
In similar cases filed elsewhere, Lilly has typically asserted federal trademark infringement, false designation of origin, and false advertising under the Lanham Act, together with state-law unfair competition claims.5Safe Medicines. Complaint, Eli Lilly v. Totality Medispa LLC The theory: compounders that reference the Mounjaro or Zepbound names in marketing lead patients to believe their products are FDA-approved or clinically equivalent to Lilly’s, when the compounded versions are, in Lilly’s words, “untested” and “potentially dangerous.”6Houston Public Media. Eli Lilly Sues Houston-Based Compounding Pharmacy Over Alleged Knockoff Obesity, Diabetes Drugs
Lilly has generally sought permanent injunctions barring use of its trademarks, corrective advertising, disgorgement of profits, and damages.5Safe Medicines. Complaint, Eli Lilly v. Totality Medispa LLC One boundary is worth flagging: federal appeals courts have held there is no private right of action to enforce the compounding rules of the Food, Drug, and Cosmetic Act directly. Lilly cannot sue Southend for violating 503A requirements as such; it has to route its case through trademark, false-advertising, and unfair-competition theories.
Why the Lawsuit Is Happening Now
Tirzepatide sat on the FDA’s drug shortage list for years, and while it was there, both 503A pharmacies and 503B outsourcing facilities could legally compound versions of it under a shortage exception to the rule against making “essentially copies” of commercial products.
That door closed on December 19, 2024, when the FDA declared the tirzepatide shortage resolved. The agency gave 503A pharmacies until February 17, 2025, and 503B outsourcing facilities until March 19, 2025, to wind down.7U.S. Food and Drug Administration. FDA Memorandum on Tirzepatide Shortage Resolution After those dates, compounding tirzepatide copies became, in the FDA’s view, a violation of federal law. Semaglutide came off the shortage list on a similar timeline in February 2025.8U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
The Outsourcing Facilities Association challenged the FDA’s determinations in the Northern District of Texas. Judge Mark Pittman denied a preliminary injunction on tirzepatide on March 5, 2025, ruling the FDA’s shortage decisions are informal adjudications within the agency’s authority. He denied a semaglutide injunction on April 24, 2025, and denied a further challenge in March 2026.8U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize9The Hill. Court Ruling on Compounding Pharmacies, FDA, and Tirzepatide With the regulatory backdrop firmly in Lilly’s favor, the company escalated its private litigation, and Southend was one of the pharmacies swept in.
How Similar Cases Have Gone
Lilly’s campaign has produced uneven results. The company has secured permanent injunctions against some defendants, and in the Washington-state Alderwood case a judge ruled in March 2025 that the Food, Drug, and Cosmetic Act does not preempt Lanham Act claims, letting Lilly’s trademark and false-advertising theories proceed even where FDA-regulated conduct is involved.10CaseMine. Eli Lilly v. Alderwood Surgical Center LLC
Other cases have stumbled. In October 2025, a judge in the District of Delaware dismissed Lilly’s suit against Arizona-based Strive Pharmacy for lack of personal jurisdiction, finding Strive’s national website was not “expressly aimed” at Delaware. The judge told Lilly to refile elsewhere and separately observed the suit appeared to lack merit beyond the jurisdictional defect.11Bloomberg Law. Judge Drops Eli Lillys Suit Over Compounded Zepbound, Mounjaro12United States District Court for the District of Delaware. Eli Lilly v. Strive Pharmacy LLC, 1:25-cv-00401-SB Strive turned around and sued Lilly and Novo Nordisk in the Western District of Texas, accusing them of a “coordinated effort to suppress competition.”13Pharmaceutical Technology. Compounder Sues Lilly and Novo for Suppressing GLP-1RA Competition The mixed record matters for Southend because Lilly filed in Texas, likely avoiding the jurisdictional problem it hit in Delaware and putting the case on the same procedural ground where other Houston-based pharmacies are litigating.
What Will Decide the Southend Case
The central factual question is how Southend marketed its compounded tirzepatide. If the pharmacy referenced Mounjaro or Zepbound in materials sent to providers, telehealth partners, or patients, Lilly’s false-advertising and trademark claims have real traction. If Southend used only the generic name tirzepatide, Lilly’s case gets harder.
The formulation question runs alongside it. Southend’s website lists “Tirzepatide / Pyridoxine HCl” as an available product, and compounders have argued that adding another active ingredient like B6 makes a product something other than an “essentially a copy” of Mounjaro or Zepbound. The FDA has taken the opposite position: combining a GLP-1 drug with another ingredient still counts as essentially a copy when the strengths are within 10% and the route of administration is the same.8U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize Because the FDA’s transition period for 503A pharmacies expired in February 2025, any tirzepatide compounding after that date is out of step with federal policy, and Lilly will use that regulatory posture to color its Lanham Act arguments.
What’s at Stake
Pharmacy defendants have consistently framed Lilly’s litigation as an effort to eliminate lower-cost competition for GLP-1 medications that can run over $1,000 a month.6Houston Public Media. Eli Lilly Sues Houston-Based Compounding Pharmacy Over Alleged Knockoff Obesity, Diabetes Drugs Lilly calls its campaign a public-safety matter, and after the March 2026 ruling declared the outcome “marks the end of the road for mass compounding of risky, unapproved knockoffs.”9The Hill. Court Ruling on Compounding Pharmacies, FDA, and Tirzepatide
The regulatory pressure is stacking. In February 2026 the FDA said it would use “all available enforcement tools,” including seizure and injunctions, against compounders making unsubstantiated marketing claims about GLP-1 products, and FDA Commissioner Marty Makary announced a broader crackdown on illegal GLP-1 compounders in October 2025.13Pharmaceutical Technology. Compounder Sues Lilly and Novo for Suppressing GLP-1RA Competition Lilly holds statutory exclusivity over tirzepatide until at least June 2027, meaning no generic can be approved before then.14The Hill. Court Ruling on Compounding Pharmacies, FDA, and Tirzepatide Novo Nordisk estimated in January 2026 that roughly 1.5 million U.S. patients were still using compounded GLP-1 medications.
Whether Southend can keep compounding tirzepatide comes down to two things: how the Texas court rules on Lilly’s trademark and false-advertising claims, and how aggressively the FDA follows through on its post-shortage enforcement promises. Providers and patients who rely on Southend’s compounded products should watch the docket and expect the pharmacy’s tirzepatide offerings to be at risk regardless of the case’s ultimate outcome.